Lenti-AS-566 sensitized glioma cells to the effects of nimotuzumab in a mice xenograft model. (A) Bioluminescence images from nimotuzumab and/or lenti-AS-566-treated animals at 3, 11 and 21 d after tumor implantation. (B) Tumor growth curves were evaluated. The data are shown as the mean ± SD. **, P < 0.01. (C) Improved survival was observed in mice that were treated with the combined therapy.